The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
- Authors:
- Liang Liu
- Jinfeng Xiang
- Rufu Chen
- Deliang Fu
- Defei Hong
- Jihui Hao
- Yixiong Li
- Jiangtao Li
- Shengping Li
- Yiping Mou
- Gang Mai
- Quanxing Ni
- Li Peng
- Renyi Qin
- Honggang Qian
- Chenghao Shao
- Bei Sun
- Yongwei Sun
- Min Tao
- Bole Tian
- Hongxia Wang
- Jian Wang
- Liwei Wang
- Wei Wang
- Weilin Wang
- Jun Zhang
- Gang Zhao
- Jun Zhou
- Xianjun Yu
-
Affiliations: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China, Department of Pancreaticobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China, Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, P.R. China, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China, Department of Pancreatic-Bililary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China, Department of Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China, Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China, Department of Gastroenterological and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, P.R. China, Department of Hepatobiliopancreatic Surgery, The People's Hospital of Deyang, Deyang, P.R. China, Department of Hepato-Pancreato-Biliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China, Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China, Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, P.R. China, Department of Pancreatic-Biliary Surgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, P.R. China, Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China, Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, P.R. China, Department of Medical Oncology, The First Hospital Affiliated to Soochow University, Suzhou, P.R. China, Department of Hepato-Biliary-Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China, Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, P.R. China, Department of Medical Oncology, Shanghai First People's Hospital, Shanghai, P.R. China, Department of Surgery, Huadong Hospital, Fudan University, Shanghai, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Hangzhou, Zhejiang, P.R. China, Department of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China, Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, Department of Medical Oncology, Peking University School of Oncolocy, Beijing Institute for Cancer Research, Beijing, P.R. China - Published online on: December 30, 2015 https://doi.org/10.3892/ijo.2015.3316
- Pages: 900-907
This article is mentioned in:
Abstract
|
Dalton WS and Friend SH: Cancer biomarkers - an invitation to the table. Science. 312:1165–1168. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, Goggins MG, Van Seuningen I, Maitra A and Montgomery EA: Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 43:1755–1763. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bafna S, Kaur S and Batra SK: Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bocheva Y, Bochev P and Ivanov S: Ca-125 in diagnosis and monitoring of patients with ovarian cancer. Akush Ginekol (Sofiia). 54:11–17. 2015.In Bulgarian. | |
|
Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M and Nowak-Markwitz E: Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Ginekol Pol. 86:88–93. 2015. View Article : Google Scholar | |
|
Gadducci A, Menichetti A, Guiggi I, Notarnicola M and Cosio S: Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. Anticancer Res. 35:1099–1104. 2015.PubMed/NCBI | |
|
Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J, et al: A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/ml indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 136:2216–2227. 2015. View Article : Google Scholar | |
|
Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, Jin CH, Yang YT and Feng XS: Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryo-ablation in pancreatic cancer patients. Cell Biochem Biophys. Dec 9–2014.Epub ahead of print. | |
|
Okada K, Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, Kitahata Y and Yamaue H: Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 21:648–653. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl 3): 274–281. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bressan A, Bozzo F, Maggi CA and Binaschi M: OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. Dis Markers. 34:257–267. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, et al: MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 13:1292014. View Article : Google Scholar : PubMed/NCBI | |
|
Govindarajan B and Gipson IK: Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res. 90:655–663. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tyler C, Kapur A, Felder M, Belisle JA, Trautman C, Gubbels JA, Connor JP and Patankar MS: The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia. Am J Reprod Immunol. 68:28–37. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rachagani S, Torres MP, Kumar S, Haridas D, Baine M, Macha MA, Kaur S, Ponnusamy MP, Dey P, Seshacharyulu P, et al: Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: Potential implications for diagnosis and therapy. J Hematol Oncol. 5:682012. View Article : Google Scholar : PubMed/NCBI | |
|
Gipson IK and Argüeso P: Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol. 231:1–49. 2003. View Article : Google Scholar | |
|
Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, et al: Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One. 6:e268392011. View Article : Google Scholar : PubMed/NCBI | |
|
Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM and Batra SK: MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene. 31:805–817. 2012. View Article : Google Scholar : | |
|
Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D and Felip E: Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, Batra SK and Yonezawa S: Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 79:101–106. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Togami S, Nomoto M, Higashi M, Goto M, Yonezawa S, Tsuji T, Batra SK and Douchi T: Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res. 36:588–597. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Argüeso P, Guzman-Aranguez A, Mantelli F, Cao Z, Ricciuto J and Panjwani N: Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem. 284:23037–23045. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SH, Hung WC, Wang P, Paul C and Konstantopoulos K: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 3:18702013. View Article : Google Scholar : PubMed/NCBI | |
|
Giannakouros P, Comamala M, Matte I, Rancourt C and Piché A: MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. Am J Cancer Res. 5:219–230. 2015. | |
|
Ricardo S, Marcos-Silva L, Pereira D, Pinto R, Almeida R, Söderberg O, Mandel U, Clausen H, Felix A, Lunet N, et al: Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol. 9:503–512. 2015. View Article : Google Scholar | |
|
Kufe DW: Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DH, Yun HY, Ryu DH, Han HS, Han JH, Yoon SM and Youn SJ: Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World J Gastroenterol. 21:1216–1221. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Paulson AS, Tran Cao HS, Tempero MA and Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shimada H, Noie T, Ohashi M, Oba K and Takahashi Y: Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 17:26–33. 2014. View Article : Google Scholar | |
|
Li Y, Li DJ, Chen J, Liu W, Li JW, Jiang P, Zhao X, Guo F, Li XW and Wang SG: Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma. Asian Pac J Cancer Prev. 16:3451–3455. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ballehaninna UK and Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 3:105–119. 2012.PubMed/NCBI | |
|
Cwik G, Wallner G, Skoczylas T, Ciechanski A and Zinkiewicz K: Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 141:968–973; discussion 974. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, et al: Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: Implications for early disease detection. Clin Cancer Res. 21:622–631. 2015. View Article : Google Scholar | |
|
Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 85:350–355. 1990.PubMed/NCBI | |
|
Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP and Blasutig IM: Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 20:5787–5795. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Menczer J, Ben-Shem E, Golan A and Levy T: The significance of normal pretreatment levels of CA125 (<35 U/mL) in epithelial ovarian carcinoma. Rambam Maimonides Med J. 6:e00052015. View Article : Google Scholar : | |
|
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q and Yu X: CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 17:2092–2098. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou P, Qu H, Shi H, Sun G and He Q: Predictive value of CA125 in peritoneal metastasis and prognosis of patients with gastric carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi. 17:1027–1030. 2014.In Chinese. PubMed/NCBI | |
|
Hartwig W, Werner J, Jäger D, Debus J and Büchler MW: Improvement of surgical results for pancreatic cancer. Lancet Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar | |
|
Simeone DM and Pandol SJ: The pancreas: Biology, diseases, and therapy. Gastroenterology. 144:1163–1165. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Du F and Chen X: Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J Surg Oncol. 12:3332014. View Article : Google Scholar : PubMed/NCBI | |
|
Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, et al: Expression of the carboxy-terminal portion of MUC16/CA125 induces transformation and tumor invasion. PLoS One. 10:e01266332015. View Article : Google Scholar : PubMed/NCBI | |
|
Das S, Rachagani S, Torres-Gonzalez MP, Lakshmanan I, Majhi PD, Smith LM, Wagner KU and Batra SK: Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget. 6:5772–5787. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hoshino M, Kawashima H, Ogose A, Kudo N, Ariizumi T, Hotta T, Umezu H, Hatano H, Morita T, Nishio J, et al: Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma. J Cancer Res Clin Oncol. 136:457–464. 2010. View Article : Google Scholar | |
|
Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, Xu J, Zhang YJ, Chen RH, Liu L, et al: Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 41:1093–1102. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, et al: (18)F-FDG PET/CT can be used to detect nonfunctioning pancreatic neuroendocrine tumors. Int J Oncol. 45:1531–1536. 2014.PubMed/NCBI | |
|
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, et al: Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett. 360:227–233. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang J, Liu L, Wang W, Xu H, Wu C, Xu J, Liu C, Long J, Ni Q and Yu X: Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC. Cancer Lett. 359:165–168. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mercadal L: Tumour markers in chronic kidney disease. Nephrol Ther. 11:122–124. 2015.In French. View Article : Google Scholar : PubMed/NCBI | |
|
Ng WW, Tong KJ, Tam TN and Lee SD: Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi (Taipei). 55:438–446. 1995. | |
|
Chen T, Zhang MG, Xu HX, Wang WQ, Liu L and Yu XJ: Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 94:e7512015. | |
|
Lai H, Jin Q, Lin Y, Mo X, Li B, He K and Chen J: Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer. Tumour Biol. 35:10547–10554. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chanvorachote P, Luanpitpong S, Chunhacha P, Promden W and Sriuranpong V: Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncol Lett. 4:252–256. 2012.PubMed/NCBI | |
|
Kawabe T, Hirano M, Mohri M, Sugimoto T, Nagata Y, Hisada M, Muto H, Unuma T, Momose T, Naka H, et al: CA125 in patients with pleural effusion - in comparison with ascites patients. Rinsho Byori. 35:905–909. 1987.In Japanese. PubMed/NCBI | |
|
Duraker N, Hot S, Polat Y, Höbek A, Gençler N and Urhan N: CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 95:142–147. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Parsons CM, Sutcliffe JL and Bold RJ: Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 15:429–435. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L and Linehan DC: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 16:1727–1733. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F and Jorba R: Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol. 178:821–826. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Maithel SK, Maloney S, Winston C, Gonen M, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF and Allen PJ: Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 15:3512–3520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Addeo P, Rosso E, Fuchshuber P, Oussoultzoglou E, De Blasi V, Simone G, Belletier C, Dufour P and Bachellier P: Resection of borderline resectable and locally advanced pancreatic adenocarcinomas after neoadjuvant chemotherapy. Oncology. 89:37–46. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Naik R and Barton DP: Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med. 363:2370–2371; author reply 2372. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pross M, Wellner UF, Honselmann KC, Jung C, Deichmann S, Keck T and Bausch D: Neoadjuvant therapy in pancreatic cancer: Review article. JOP. 16:110–114. 2015.PubMed/NCBI | |
|
Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E and Barni S; Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD). FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies. Pancreas. 44:515–521. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, et al: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pelissier A, Bonneau C, Chéreau E, de La Motte Rouge T, Fourchotte V, Daraï E and Rouzier R: CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 135:542–546. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mou W, Liu Z, Luo Y, Zou M, Ren C, Zhang C, Wen X, Wang Y and Tian Y: Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients. Med Oncol. 31:592014. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang GI, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, Kim YS, Han WK and Pae WK: Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat. 36:178–181. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G and Pisano C: Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol. 22(Suppl 8): viii40–viii44. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Myriokefalitaki E, Vorgias G, Vlahos G and Rodolakis A: Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer. Arch Gynecol Obstet. 292:647–654. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Z and Zhang N: Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 12:3972014. View Article : Google Scholar : PubMed/NCBI | |
|
Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, et al: Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 17:1794–1801. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Škrha P, Hořínek A, Anděl M and Škrha J: miRNA-192, miRNA-21 and miRNA-200: New pancreatic cancer markers in diabetic patients? Vnitr Lek. 61:351–354. 2015.In Czech. | |
|
Körner M, Waser B, Strobel O, Büchler M and Reubi JC: Neurotensin receptors in pancreatic ductal carcinomas. EJNMMI Res. 5:172015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zuo CJ, Jia NY, Wang JH, Hu SP, Yu ZF, Zheng Y, Zhang AY and Feng XY: Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer. World J Gastroenterol. 21:2988–2996. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Okano K, Oshima M, Yamamoto N and Suzuki Y: PET imaging in the diagnosis of pancreatic cancer. Nihon Rinsho. 73(Suppl 3): 79–83. 2015.In Japanese. | |
|
Wang Z and Tian YP: Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Mol Clin Oncol. 2:265–268. 2014.PubMed/NCBI | |
|
Yang Y, Chen H, Wang D, Luo W, Zhu B and Zhang Z: Diagnosis of pancreatic carcinoma based on combined measurement of multiple serum tumor markers using artificial neural network analysis. Chin Med J (Engl). 127:1891–1896. 2014. | |
|
Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A and Lokshin AE: Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One. 9:e949282014. View Article : Google Scholar : PubMed/NCBI | |
|
Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H and Koong AC: Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 7:1052009. View Article : Google Scholar : PubMed/NCBI |
